- ￥225 - 3136
- TargetMol
- T5492
- 2026年07月07日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- CAS号：
1443235-95-7
- 规格：
1mg/1mLx10mM(inDMSO)/2mg/5mg/10mg/25mg/50mg/100mg
| 规格： | 1mg | 产品价格： | ￥225.0 |
|---|---|---|---|
| 规格： | 1mLx10mM(inDMSO) | 产品价格： | ￥510.0 |
| 规格： | 2mg | 产品价格： | ￥311.0 |
| 规格： | 5mg | 产品价格： | ￥462.0 |
| 规格： | 10mg | 产品价格： | ￥730.0 |
| 规格： | 25mg | 产品价格： | ￥1320.0 |
| 规格： | 50mg | 产品价格： | ￥2184.0 |
| 规格： | 100mg | 产品价格： | ￥3136.0 |
Product Introduction
Bioactivity
| 名称 | JAK3-IN-6 |
| 描述 | JAK3-IN-6 is irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC50 of 0.15 nM |
| 动物实验 | Female Lewis rats were purchased and housed . 48 rats were divided into six groups (n=8/group). Group 1 were drug-na?ve i.e. no compounds were administered throughout the study. On the afternoon of Day 1 (4pm), ABT or vehicle (1 ml/kg p.o.) was administered to Groups 2-5. Days 2-11 (8 am), each animal in Groups 2-5 were administered ABT 10 mpk qd (1 ml/kg p.o.), immediately followed by either vehicle or compound at 5ml/kg p.o. Group 6 animals received vehicle only (5 ml/kg p.o.). Days 2-11 (4 pm) Groups 2-5 were administered vehicle or compound at 5 ml/kg p.o. Animals were monitored and weighed throughout the study. On Day 10, under isoflurane anesthesia, 3 animals from Groups 2-6 were bled via the jugular vein for PK analysis at 4 and 8 h post-8 am dose. On Day 11, blood samples were collected, as described above, at 0 (16 h post-Day 10 pm dose) and 2 h post-am dose for PK, hematology, and clinical chemistry analysis. All remaining animals were euthanized at 2 hrs post-dosing on Day 11 and blood samples were collected for PK, hematology, and clinical chemistry analysis. Data were analyzed using Graphpad prism software. Statistical analyses were performed using a one-way ANOVA with Dunnett s post-hoc test for group comparisons to ABT + vehicle treatment. |
| 体外活性 | 一种强效的JAK3抑制剂（0.15 nM）在酶类实验中对JAK3的选择性是对JAK1的4300倍，而在细胞报告实验中对IL-2相比IL-6的选择性是67倍，对IL-2相比EPO或GMCSF的选择性是140倍，在人类PBMC实验中对IL-7相比IL-6或GMCSF的选择性是大于35倍。在体内，选择性抑制JAK3足以阻断炎症在类风湿关节炎大鼠模型中的发展，并且不影响造血。 |
| 存储条件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 溶解度 | DMSO : 250 mg/mL (713.53 mM), Sonication is recommended. 10% DMSO+90% Saline : < 10 mg/mL (28.54 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 10 mg/mL (28.54 mM), Solution. |
| 关键字 | Janus kinase | JAK3-IN-6 | JAK-3-IN-6 | JAK3IN6 | JAK3 IN 6 | JAK3 | JAK | Inhibitor | inhibit |
| 相关产品 | JAK-IN-10 | Tofacitinib Citrate | Ruxolitinib | Raspberry ketone glucoside | Lentinan | Resveratrol | Filgotinib | Tofacitinib | 2-(1,8-naphthyridin-2-yl)phenol | Atinvicitinib | 2,4,5-Trimethoxybenzoic acid | Delgocitinib |
| 相关库 | Inhibitor Library | Bioactive Compound Library | Bioactive Compounds Library Max | Kinase Inhibitor Library | Apoptosis Compound Library | Highly Selective Inhibitor Library | Anti-Aging Compound Library | Stem Cell Differentiation Compound Library | Anti-Lung Cancer Compound Library | Immunology/Inflammation Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验网络 第十九章 杂环化合物和生物碱 杂环化合物在自然界分布很广，其数量几乎占已知有机化合物的三分之一，用途也很多。许多重要的物质如叶绿素、血红素、核酸以及临床应用的一些有显著疗效的天然药物和合成药物等，都含有杂环化合物的结构。生物碱多是中草药的有效成分，绝大多数是含氮的杂环化合物。本章内容与医学关系密切，具有重要意义。
分子中具有高能键的化合物。在生物体内主要有上式（Ⅰ）和（Ⅱ）两种结构的高能化合物。其作用为贮藏能量（例如 ATP、肌酸磷酸）和作为产生 ATP源的中间代谢产物（例如磷酸烯醇丙酮酸）以及合成反应的中间物质（例如酰基辅酶 A），在蛋白质的结构（ conformation）变化周期的第一阶段上（例如钠钾 ATP酶的羧基磷酸中间体）也具有重要作用。多数高等化合物具有磷酸基，但也有例外。
由不同种元素组成的纯净物叫做化合物。化合物一般有固定的组成。化合物的组成一般可用化学式表示。化合物具有确定的物理性质和化学性质，不同于其组成元素的性质。化合物中的元素不能用简单的机械方法或物理方法分开，而必须用化学方法才能分离。
技术资料暂无技术资料 索取技术资料
